ALBRIOZA Commercial Launch

Europe Path to commercialization TOD Significant Unmet Need in Europe 30,000+ people are living with ALS in the EU and U.K.1 There is a crucial need for new, effective treatments for ALS in Europe, which only has one approved therapy (Riluzole), and no new therapies in over 25 years Riluzole is prescribed to 75-90% of people living with ALS across Germany, France, Spain, Italy, and the U.K.2 Targeted, Local Commercial Approach Actively preparing launch in the EU and engaging with key stakeholders in each member state. Expect to launch in Germany first, followed by expansion in additional countries; reimbursement process and timelines differ by country Working with ALS community and reimbursement bodies to facilitate access to ALBRIOZAⓇ, if approved Experienced, Established Local Leadership Team Accomplished cross functional leadership team in place developing commercialization strategy for ALBRIOZA in EMEA and ensuring its implementation, including Regional Head of EMEA, Head of EMEA Market Access, Head of EMEA Regulatory, Head of EMEA Medical, and GMs for major European markets, including Germany Continuing to build a highly targeted and lean team References: 1. Chiò /Logroscino/Traynor/Collins / Simeone/Goldstein/Nelson LM, et al. Neuroepidemiology. 2021 Dec 20. doi: 10.1159/000521591. 2. Source: IQVIA MIDAS data. AMYLYX 16

View entire presentation